Autopsy report · NCT04126343

A Study to Test the Cardiac Effects of Padsevonil in Healthy Study Participants

“Based on available data, UCB has decided to stop development of padsevonil as adjunctive treatment of focal-onset seizures”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 7 months before it stopped.
• 54 participants enrolled.
• Results were posted on the registry 1 year 1 month after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

UCB Biopharma S.P.R.L.

Sponsor type

Industry

Conditions

Healthy Study Participants

Interventions

Padsevonil; Moxifloxacin; Placebo

Participants

54

Sites

1

Countries

United Kingdom

Trials that died the same way

• Verapamil and Catamenial Epilepsy
  “protocol changed and a new study using verapamil in epilepsy will be started in the near future” (61% match in meaning)
• Randomized Trial Comparing 3 Routes of Delivering Lorazepam to Children.
  “The buccal arm of the study was 30% less effective in stopping seizures within 10 minutes compared with the IV dose. This met a stopping rule for the study” (56% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.